Skip to content

effect of statin in COVID19

Evaluation of statin effect on COVID19 duration and complications

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20201128049508N1
Enrollment
60
Registered
2020-12-28
Start date
2020-09-22
Completion date
Unknown
Last updated
2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid 19. Coronavirus as the cause of diseases classified elsewhere

Interventions

Sponsors

Ghoum University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age over 18 No history of statin use in the past Oxygen saturation above 93% by receiving oxygen reservation bag Liver enzymes in the normal range Lack of musculoskeletal disease such as myopathy. Known neuropathy Do not take drugs that interfere with the use of statins as defined by the FDA

Exclusion criteria

Exclusion criteria: People with kidney disease in the ESRD stage, in other words GFR less than 15 Cardiogenic shock Recent acute renal failure-Severe heart-liver failure Patients with transplanted kidney People who have had CT Angio-MR Angio-Angiography in the last 2 weeks. Receiving nephrotoxic substances during the last two weeks Instability of the patient's hemodynamic status History of taking statins Increase CPK (double)AST (triple) SPO2 below 93% despite receiving oxygen reservation bag

Design outcomes

Primary

MeasureTime frame
Death. Timepoint: every day. Method of measurement: View.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Bagherzadeh

Ghoum University of Medical Sciences

mbagherzadeh@muq.ac.ir+98 25 3612 2000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026